ESSA Pharma Inc. announced the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer. With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing. Prior to joining ESSA, Dr. Cesano was the CMO at NanoString Technologies Inc.